PSMA ADC in treatment of mCRPC post-chemo and post-abiraterone and/or enzalutamide

Data from an open-label Phase II trial of PSMA ADC — a fully human IgG1 antibody conjugated to monomethyl auristatin E (MMAE) — suggests that this agent has activity in treatment of metastatic, castration-resistant prostate cancer (mCRPC) patients who have already progressed on abiraterone acetate and/or enzalutamide. … READ MORE …

PSMA-ADC shows positive results in Phase I clinical trial in advanced mCRPC

According to data presented today at the Symposium on Molecular Targets and Cancer Therapeutics in Dublin, Ireland, a new type of targeted drug therapy has shown early positive results in men with metastatic, castration-resistant porstate cancer (mCRPC) who had also failed at least two forms of chemotherapy. … READ MORE …